Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

US Patent 12161714 · Granted Dec 10, 2024

Estimated economic value: $26,297,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CAR for treatment of HIV infection2025
CS1 targeted chimeric antigen receptor-modified T cells2025
Use of triplex CMV vaccine in CAR T cell therapy2025
Use of triplex CMV vaccine in CAR T cell therapy2025
Administration of engineered T cells for treatment of cancers in the central ner2025
Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 pos2025
Activatable masked anti-CTLA4 binding proteins2025
Oncolytic virus expressing a car T cell target and uses thereof2025
Anti-CD6 antibody-growth factor complex for treating autoimmune diseases2025
Genetically stable recombinant modified vaccinia Ankara (RMVA) vaccines and meth2025
CD6 targeted chimeric antigen receptors for treatment of certain autoimmune diso2025
TAG72 targeted chimeric antigen receptor modified T cells for treatment of TAG722025